377 results on '"Wong, Pancras C"'
Search Results
2. Advances in Clinical and Basic Science of Coagulation: Illustrated abstracts of the 9th Chapel Hill Symposium on Hemostasis
3. Improved efficacy/safety profile of factor XIa inhibitor BMS‐724296 versus factor Xa inhibitor apixaban and thrombin inhibitor dabigatran in cynomolgus monkeys
4. Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding
5. The P2Y1 receptor antagonist MRS2500 prevents carotid artery thrombosis in cynomolgus monkeys
6. Abstract 13794: An Orally-Active Small-Molecule Antagonist of the Platelet Protease-Activated Receptor-4, BMS-986141, Prevents Aeterial Thrombosis With Low Bleeding Liability in Cynomolgus Monkeys
7. In vitro, antithrombotic and bleeding time studies of BMS-654457, a small-molecule, reversible and direct inhibitor of factor XIa
8. Calibration and validation of the rabbit model of electrolytic‐mediated arterial thrombosis against the standard‐of‐care anticoagulant apixaban
9. Angiotensin Antagonists in Models of Hypertension
10. Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy
11. Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor
12. A small-molecule factor XIa inhibitor produces antithrombotic efficacy with minimal bleeding time prolongation in rabbits
13. Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor
14. Metabolism, pharmacokinetics and pharmacodynamics of the factor Xa inhibitor apixaban in rabbits
15. Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits
16. Case History
17. Discovery of a High Affinity, Orally Bioavailable Macrocyclic FXIa Inhibitor with Antithrombotic Activity in Preclinical Species
18. Inhibition of Factor Xa Reduces Ischemic Brain Damage After Thromboembolic Stroke in Rats
19. Nonpeptide angiotensin II receptor antagonists
20. Potent, Orally Bioavailable, and Efficacious Macrocyclic Inhibitors of Factor XIa. Discovery of Pyridine-Based Macrocycles Possessing Phenylazole Carboxamide P1 Groups
21. Nonpeptide Angiotensin II Receptor Antagonist: Losartan
22. Contributors to Volume 13
23. Neutral macrocyclic factor VIIa inhibitors
24. Advances in Clinical and Basic Science of Coagulation: Illustrated abstracts of the 9th Chapel Hill Symposium on Hemostasis
25. Synthesis and P1′ SAR exploration of potent macrocyclic tissue factor-factor VIIa inhibitors
26. Novel phenylalanine derived diamides as Factor XIa inhibitors
27. Correction to “Atropisomer Control in Macrocyclic Factor VIIa Inhibitors”
28. On the article “Drugs targeting protease-activated receptor-4 improve the anti-thrombotic therapeutic window”
29. Preparation of pyrrolidine and isoxazolidine benzamidines as potent inhibitors of coagulation factor Xa
30. Design and synthesis of potent and selective 5,6-fused heterocyclic thrombin inhibitors
31. Design and synthesis of potent, selective phenylimidazole-based FVIIa inhibitors
32. Discovery of a Parenteral Small Molecule Coagulation Factor XIa Inhibitor Clinical Candidate (BMS-962212)
33. Abstract TMP117: Preclinical and Early Clinical Characterization of a Parenterally Administered Direct Factor XIa Inhibitor
34. Potent, Orally Bioavailable, and Efficacious Macrocyclic Inhibitors of Factor XIa. Discovery of Pyridine-Based Macrocycles Possessing Phenylazole Carboxamide P1 Groups
35. Discovery of a Parenteral Small Molecule Coagulation Factor XIa Inhibitor Clinical Candidate (BMS-962212)
36. Nonbenzamidine acylsulfonamide tissue factor–factor VIIa inhibitors
37. Discovery of diarylurea P2Y1 antagonists with improved aqueous solubility
38. Discovery and gram-scale synthesis of BMS-593214, a potent, selective FVIIa inhibitor
39. Design and synthesis of bicyclic pyrazinone and pyrimidinone amides as potent TF–FVIIa inhibitors
40. Design and Synthesis of Novel Meta-Linked Phenylglycine Macrocyclic FVIIa Inhibitors
41. Discovery of Phenylglycine Lactams as Potent Neutral Factor VIIa Inhibitors
42. Discovery of a Highly Potent, Selective, and Orally Bioavailable Macrocyclic Inhibitor of Blood Coagulation Factor VIIa–Tissue Factor Complex
43. Atropisomer Control in Macrocyclic Factor VIIa Inhibitors
44. Abstract 175: A Novel Orally-Active Small-Molecule Antagonist of the Platelet Protease-Activated Receptor-4, BMS-986120, Inhibits Arterial Thrombosis With Limited Impact on Hemostasis in Cynomolgus Monkeys
45. Chapter Nine - Case History: Eliquis™ (Apixaban), a Potent and Selective Inhibitor of Coagulation Factor Xa for the Prevention and Treatment of Thrombotic Diseases
46. The P2Y1 receptor antagonist MRS2500 prevents carotid artery thrombosis in cynomolgus monkeys
47. Structure-Based Design of Macrocyclic Coagulation Factor VIIa Inhibitors
48. Discovery of a Potent Parenterally Administered Factor XIa Inhibitor with Hydroxyquinolin-2(1H)-one as the P2′ Moiety
49. Phenylimidazoles as Potent and Selective Inhibitors of Coagulation Factor XIa with in Vivo Antithrombotic Activity
50. New advances in treating thrombotic diseases
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.